TXG — 10x Genomics, Inc.

10x Genomics invented the dominant commercial platforms for single-cell and spatial transcriptomics, holds the patent moat that sustains 69% gross margins in a field where competitors have tried for a decade to displace it, and sits at the center of one of the most consequential technological transitions in modern biology. The investment today fails on one specific, observable condition: instrument placements collapsed 39% in 2025, and without new instruments entering laboratories, the installed base that drives consumables revenue cannot grow. The catalyst required to make this actionable is a recovery in academic research funding — specifically the NIH budget environment — sufficient to restart the instrument placement cycle; if that recovery arrives, the stock is cheap; if it does not, the consumables base ages without renewal and the business erodes despite the technology.

---

The biomedical research funding environment in 2025 and 2026 is the worst in a generation for life science tools companies. The National Institutes of Health, which distributes approximately $47 billion annually to academic researchers, has faced budget pressures that have reduced the velocity of grant awards, increased grant renewal uncertainty, and caused laboratory purchasing managers to defer capital equipment decisions with a severity not seen since 2013. The problem is not merely cyclical; it reflects deliberate policy decisions that have created multi-year budget uncertainty for the academic institutions that collectively represent the largest customer segment for precision biology instrumentation. Every major tools company — Illumina, Pacific Biosciences, Fluidigm — has cited the same environment. 10x Genomics is not an exception, and the problem is not unique to its competitive position. This context is essential for reading the company's 2025 results honestly.

What makes the 2025 funding environment particularly punishing for 10x Genomics is the structure of its business model. The company sells instruments and consumables in a classical razor-and-blade configuration: instruments are placed at relatively low gross margins, creating a recurring consumables revenue stream that is subsequently captured at high margins for the life of the instrument. The instrument is the investment; the consumables are the return on that investment. A sharp decline in instrument placements does not immediately destroy revenues — the existing installed base continues generating consumables demand — but it does signal that future consumables revenue will not grow unless the placement rate recovers. This is the analytical key to 10x Genomics: the instrument placement number is a leading indicator for consumables revenue growth one to three years forward. In 2025, instrument placements declined 39%.

Single-cell and spatial genomics are not niche technologies. The ability to measure gene expression at the resolution of individual cells — rather than averaging across millions of cells in bulk tissue — has transformed oncology, immunology, neuroscience, and developmental biology research over the past decade. A conventional tumor biopsy tells you what genes are expressed by the tumor on average. A single-cell analysis tells you which cells within that tumor are drug-resistant, which are actively proliferating, and which have undergone immune evasion — the information that determines why a patient responds to one therapy and not another. Spatial transcriptomics goes further: it preserves the physical location of each cell within a tissue section, revealing how cellular neighborhoods interact in ways that single-cell analysis, which requires cell dissociation, cannot capture. The technology has moved from research curiosity to standard protocol at major cancer centers in less than five years. The market for single-cell analysis is valued at approximately $4.9 billion in 2024 and is projected to reach $21.97 billion by 2035 at a 16.5% compound annual growth rate.

The industry structure has two tiers. At the top are platforms with proprietary chemistry and computational infrastructure — difficult to replicate, commanding significant pricing power. At the lower tier, researchers needing less sensitivity or lower throughput can choose cheaper alternatives, often from private companies like Parse Biosciences (which uses a kit-based, instrument-free single-cell approach that costs significantly less per sample) or Vizgen (which offers spatial analysis using a different optical chemistry). These lower-cost competitors have captured share at the margins of the market — smaller labs, price-sensitive academic groups, lower-throughput applications. What they have not done is penetrate the high-throughput, high-sensitivity core of the market where 10x Genomics concentrates.

10x Genomics operates two principal platforms: Chromium, for single-cell analysis via microfluidic droplet encapsulation, and Xenium, for spatial transcriptomics via in-situ RNA detection in tissue sections. Chromium has been the commercial product since 2016; it holds approximately 45 to 50% of the global single-cell analysis market. Xenium launched commercially in 2022 and is the company's highest-growth platform, generating spatial consumables revenue of $144 million in 2024, growing at 14% in 2025 despite the funding headwinds. The company also acquired Scale Biosciences in 2024, adding a combinatorial indexing approach that allows researchers to process vastly more cells per experiment than standard droplet encapsulation. The portfolio is genuinely differentiated — these are not incremental improvements on competitors' approaches, but distinct technological paradigms that produce different data types with different analytical capabilities.

The moat rests on two foundations. The first is the patent portfolio. 10x Genomics has pursued an unusually aggressive intellectual property strategy, winning or settling patent disputes against NanoString Technologies, Bio-Rad Laboratories, and others. The litigation income — $44.1 million in non-recurring revenue in 2025 — reflects the practical value of that portfolio in controlling access to core single-cell and spatial techniques. More importantly, the patents provide a floor under gross margins: a competitor who develops a faster or cheaper instrument cannot simply copy the chemistry that produces the data quality that publications, grant applications, and regulatory submissions require. The second foundation is the installed base and the software ecosystem. With 1,666 instruments placed globally, each instrument is surrounded by bioinformatics pipelines, data analysis workflows, and institutional expertise built on 10x data formats. Switching from a Chromium to a Parse Biosciences workflow requires re-validating every downstream analysis tool the laboratory uses. This switching cost is invisible in a balance sheet but is observable in the data: single-cell consumable volumes grew 22% in 2025 even as instrument placements declined sharply — existing Chromium customers are not switching away; they are running more samples per instrument.

Company	Gross Margin	Market Share (Single-Cell)	Platform Approach	Switching Cost
10x Genomics	69%	~45-50%	Microfluidics + spatial in-situ	High (proprietary libraries, bioinformatics)
Vizgen	N/A (private)	~5-10% spatial	MERFISH (optical)	Medium
Parse Biosciences	N/A (private)	~5-10% single-cell	Split-pool barcoding (no instrument)	Low
Illumina (DRAGEN)	~68%	Downstream sequencing partner	Sequencing-by-synthesis	Very high

The 69% gross margin is the number that proves the moat is real rather than asserted. Parse Biosciences, which competes on price by eliminating the instrument requirement, cannot match this margin structure because its value proposition is low-cost access. 10x Genomics maintains its margin because researchers who need high sensitivity, high throughput, and publication-validated data quality do not make the switch for a price discount. The gross margin has been stable across multiple years and competitive challenges — it is not a temporary artifact of market conditions but a structural feature of the pricing power this platform has earned.

Full-year 2025 revenue was $642.8 million, but this figure includes $44.1 million in non-recurring patent litigation settlement revenue. Adjusting for this one-time item, organic revenue was $598.7 million — a 2% decline from 2024's adjusted base. The headline number understates the deterioration. Instrument revenue collapsed from $92.7 million in 2024 to $56.8 million in 2025 — a 39% decline driven by near-equal declines in both Chromium instruments (down 36%) and spatial Xenium instruments (down 41%). Consumables revenue partially offset this: single-cell consumables grew 3% in dollar terms (with volumes up 22% — pricing pressure is evident) and spatial consumables grew 14%. The GAAP-to-adjusted divergence deserves explicit treatment: the litigation revenue is excluded from management's organic growth metrics and from the 2026 guidance range. The $61 million operating loss in 2025 represents a dramatic improvement from $194.6 million in 2024, driven by cost discipline and lower R&D spending — but at $258.6 million, R&D still represents approximately 43% of adjusted revenue. Stock-based compensation is embedded in operating expenses; GAAP net loss of $43.5 million overstates the cash consumption, as operating cash flow was $136 million — boosted in part by the litigation proceeds and working capital changes. True recurring free cash flow is substantially lower.

Management is led by CEO Serge Saxonov, a computational biologist who co-founded the company and has driven its product development since inception. The technical credibility of the team is not in doubt; the commercial execution is. The instrument placement collapse in 2025 is not primarily a product quality failure — the technology continues to be published in high-profile journals and adopted by leading academic centers. It is a go-to-market and market timing failure compounded by an external funding shock. The capital allocation record over five years is difficult to characterize positively: five-year average return on invested capital is negative 44.5%, reflecting accumulated R&D and operating losses that have not yet converted to profitable growth. There is no share repurchase program. The CEO sold shares in March 2026 at approximately $22 to $23 per share under a Rule 10b5-1 plan. The company holds $523.4 million in cash and securities — sufficient runway to fund operations through the funding cycle without an equity raise at current burn rates — but the cash balance is itself a signal that management has not identified a capital deployment opportunity that would generate better returns than holding the cash.

The instrument placement trend is the most important data series to watch.

Fiscal Year	Instrument Revenue	YoY Change	Consumables Revenue	Adjusted Total Revenue	Operating Loss
FY2022	~$124M	—	~$275M	~$400M	~($200M)
FY2023	~$110M	-11%	~$390M	~$500M	~($220M)
FY2024	$92.7M	-16%	~$518M	~$610M	($194.6M)
FY2025	$56.8M	-39%	~$542M	$598.7M	($61.0M)
FY2026E	~$55M (est.)	~flat	~$555M	$600-625M	TBD

This table captures the central tension in the investment case. Instrument revenue has declined every year for three consecutive years, dropping from approximately $124 million to $56.8 million — a 54% cumulative decline. Consumables have grown to partially offset this, but consumables revenue growth depends on an expanding installed base, and a base that grows more slowly — or ceases to grow — will eventually produce flat and then declining consumables revenue. The 22% volume growth in single-cell consumables in 2025 demonstrates that the installed base is being used intensively, not abandonmentally. This is the positive read: researchers are not walking away from their 10x instruments; they are running more experiments. The negative read is that without new instrument placements, the total addressable consumables opportunity stops expanding.

The penetration argument has two faces. On the installed base: 10x Genomics has placed 1,666 instruments globally, in an addressable market of an estimated 10,000 to 15,000 academic and translational laboratories worldwide that routinely perform single-cell or spatial analysis. Penetration is approximately 10 to 15% of the eventual installed base ceiling — substantial market remains. On the critical funding dependency: approximately 60 to 70% of the company's revenue comes from academic and publicly funded research institutions. These customers are buying instruments when grants are funded and consumables when experiments are running. The NIH budget environment — now under pressure from multiple directions including direct budget cuts and indirect competition for discretionary funds — is a constraint that 10x Genomics cannot manage around on its own.

At approximately $21 per share, 10x Genomics trades at a market capitalization of roughly $1.55 billion. After subtracting $523.4 million in cash and securities, the enterprise value assigned to the operating business is approximately $1.0 billion. Against $598.7 million in adjusted 2025 revenue, that is an EV/revenue multiple of 1.7 times — below the industry average of 2.27 times price-to-sales and well below the 3.6 times multiple that the average tools company in this space commands. The discount exists for a reason: the market is pricing in continued instrument placement weakness through 2026, flat-to-slightly-growing consumables revenue, and an uncertain path to profitability. The question is whether the discount is sufficient compensation for those risks, or whether it understates the structural headwinds ahead.

The catalyst that makes this actionable is specific: a recovery in NIH grant funding velocity sufficient to cause academic laboratory purchasing managers to restart capital equipment procurement. This is not a company-specific catalyst — it is a macro event that 10x Genomics cannot accelerate through its own actions. Management can launch new products (Xenium Protein, Scale Biosciences integration), reduce costs, and optimize pricing — all of which they are doing — but they cannot cause NIH budget approvals to accelerate. The investment therefore depends on a political and budgetary process that operates on a 12 to 18 month cycle with no certainty of timing. An investor who believes NIH funding pressure will ease in the back half of 2026 or 2027 would find the current enterprise value compelling for a business with 69% gross margins, genuine technological differentiation, and an installed base that is actively running experiments at increasing intensity. An investor who believes the funding headwind is structural — a multi-year compression of academic research budgets — would conclude that even a discounted valuation does not compensate for a growth engine that has stalled.

The most credible bear on this thesis is specific: instrument placements have been declining for three consecutive years, not one. The 2023 decline (-11%) predates the most acute funding pressures and suggests that even before the macro headwind intensified, the business was losing momentum in its most important leading indicator. The share taken by lower-cost alternatives like Parse Biosciences at the affordability end of the market may be structural, not cyclical — once a laboratory builds its workflows on a kit-based no-instrument approach, the instrument cost savings make returning to 10x Genomics difficult to justify. The answer to this bear is that single-cell consumable volumes grew 22% in 2025 despite the macro headwind, proving that 10x instruments in existing labs are generating increasing demand, not decreasing. The installed base is not being abandoned. But the bear is not wrong that three consecutive years of instrument decline is a pattern rather than an anomaly.

The technology is extraordinary. The market is real and growing. The patent moat sustains margins that would be the envy of most industrial companies. None of that is worth owning at any price if the instruments stop being placed and the installed base ages without renewal. The fund that cures this disease is Congress, not management — and until the NIH budget environment shifts, the instrument placement trend will not reverse. Watch for Q1 and Q2 2026 instrument placement figures: stabilization above $14 million per quarter, versus the implied $14 million quarterly run rate in the 2026 guidance, would be the first observable signal that the cycle has turned. A genuine reacceleration above $18 to $20 million per quarter would signal the thesis is on track and today's enterprise value of $1.0 billion would look obviously insufficient.

Compelling technology at a fair price — waiting on a catalyst that only Washington can provide.